ClinicalTrials.gg
CompletedNCT00464308Updated Apr 21, 2014Results posted

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

A Phase 4 interventional study of Esomeprazole and Rabeprazole in Gastro-oesophageal Reflux, sponsored by Janssen-Cilag Pty Ltd. Completed at 25 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.

Sponsored by Janssen-Cilag Pty Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,392
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
4th of 66
1,392 · median 125
Started
2006
with 12 others
Phase 4
28 of 67
none open now
Registered
29th of 67
by date

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 4th largest by enrollment of the 66 interventional ones that give a count, is one of 13 that started in 2006, is one of 28 in phase 4, and was the 29th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.

Read the detailed description

The study is designed to be conducted in a realistic General Practice (GP) setting, enrolling typical Gastro-oesophageal Reflux Disease (GORD) patients that present for treatment, and for whom a Proton Pump Inhibitor (PPI) would normally be prescribed. The study will be conducted over a 4-week period on the basis that current GP standard practice is to treat the GORD patient for a period of 4-weeks prior to reassessment and further follow-up if required. This study is conducted in patients with GORD - associated heartburn (with or without regurgitation) at multiple GP centers, treatment is assigned based on chance (randomized), similar to the toss of a coin and neither doctor or patient knows which treatment they will receive (double-blinded). Following screening to determine eligibility, patients will be randomized to receive oral treatment with either, 20 mg rabeprazole, 20 mg esomeprazole or 40 mg esomeprazole once daily for 4 weeks. This 4-week study encompasses 2 protocol-mandated visits (baseline on day 0 and final visit on day 28). It is hypothesized that rabeprazole 20 mg will be no less effective than (non-inferior) esomeprazole 40 mg for the degree of GORD symptom resolution. Patients will take one tablet (rabeprazole 20 mg or placebo) and one capsule (esomeprazole 20 mg, esomeprazole 40 mg or placebo) each day for 28 days. The study medication will be taken once daily in the morning before breakfast, except the first dose, which will be taken during Visit 1.

03

Conditions studied

  • Gastro-oesophageal Reflux

Keywords

  • Gastroesophageal Reflux
  • Heartburn
  • Proton pump inhibitor
  • GORD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heartburn (defined as a feeling of burning or pain, rising from the epigastrium or lower part of the chest up towards the neck) with or without regurgitation
  • Patients must have had episodes of heartburn with or without regurgitation for 3 months or longer, and for >= 3 days in the 7 days prior to randomisation
  • Able to understand and complete questionnaires, able to give written , and have access to a telephone

Exclusion criteria

Exclusion Criteria:

  • Patients requiring endoscopy within 4 weeks of randomisation or with gastrointestinal symptoms that, in the opinion of the investigator, require further investigation prior to or coincident with initiation of PPI therapy which would include, but are not limited to, alarm symptoms such as unintentional weight loss, progressive difficulty swallowing (dysphagia), iron deficiency anaemia and epigastric mass
  • Significant gastrointestinal obstruction, major gastric or oesophageal surgery (excluding appendectomy or cholecystectomy), oesophageal stricture or pyloric stenosis, extra-oesophageal manifestations of reflux disease
  • Patients with Barrett's oesophagus (>3cm), Zollinger-Ellison Syndrome, scleroderma, (other than non-melanoma skin cancers) present within the last 5 years, to rabeprazole or esomeprazole or any PPI, or any other significant condition that, in the opinion of the investigator, could interfere with the patients participation or compliance in the study such as past or current history of alcohol or drug abuse, hepatic, renal, pulmonary, respiratory abnormalities, or who have participated in an drug or investigational device study within 30 days prior to the baseline visit or who are expected to do so during the 4 week study period
  • Female patients who are currently pregnant or breast feeding, or who, in the opinion of the investigator, may become pregnant throughout the study
  • Use of histamine-2 receptor antagonists (H2RAs) within 7 days of randomisation, anticholinergics, cholinergics, spasmolytics, opiates, sucralfate, proton pump inhibitors (PPIs), prokinetics, antibiotics (in relation to H. pylori treatment) or bismuth compounds within 14 days of randomisation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,392 participants (actual)

Study arms

  • Active comparator
    001

    Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

    Drug: Esomeprazole

  • Active comparator
    002

    Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

    Drug: Esomeprazole

  • Active comparator
    003

    Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

    Drug: Rabeprazole

Interventions

  • 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

  • 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

  • 40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

06

What researchers measure

Primary outcomes

  1. The Number of Patients With Complete Resolution of Heartburn by Week 4

    Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.

    Time frame: week 4 of treatment

  2. The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4

    Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.

    Time frame: 4 weeks

  3. The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4

    Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.

    Time frame: 4 weeks

  4. The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4

    Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.

    Time frame: 4 weeks

Secondary outcomes

  1. The Median Time to Complete Resolution of Heartburn Symptoms.

    Time frame: week 4 of treatment

  2. The Median Time to Complete Relief of Regurgitation Symptoms

    Time frame: 4 weeks

  3. The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods

    Time frame: 4 weeks

07

Results

Posted Aug 30, 2010
Limitations and caveats
The MCID of 7.5% was amended to 9% to maintain power with smaller sample size.The proportion of patients without heartburn symptoms at baseline was not evenly distributed between treatment arms. This was a significant predictor of symptom resolution.

Participant flow

Participant flow — Overall Study
MilestoneRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
Started464469459
Completed395406400
Not completed696359
Withdrew: Adverse event222716
Withdrew: Lost to follow-up291920
Withdrew: Patient discontinued and other reasons171723
Withdrew: Physician decision100

Outcome measures

PrimaryThe Number of Patients With Complete Resolution of Heartburn by Week 4

Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.

Time frame:
week 4 of treatment
Reported as:
Number · participants
The Number of Patients With Complete Resolution of Heartburn by Week 4
participantsRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Number of Patients With Complete Resolution of Heartburn by Week 4272302278
Statistical analysis
  • Rabeprazole 20 mg/Day vs Esomeprazole 40 mg/Day · Non-inferiority · p = <0.05 (Adjustment for multiple comparisons was not made. The a priori threshold for statistical significance was p\<0.05. Tests were 2-sided except for the non-inferiority test which was 1-sided.) · Proportion difference: -0.11Assumed that the true resolution rates in the rab20 and eso40 groups would be 30% (0.3). Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%
SecondaryThe Median Time to Complete Resolution of Heartburn Symptoms.
Time frame:
week 4 of treatment
Reported as:
Median · days
The Median Time to Complete Resolution of Heartburn Symptoms.
daysRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Median Time to Complete Resolution of Heartburn Symptoms.11 (9 to 15)9 (7 to 10)12 (10 to 15)
SecondaryThe Median Time to Complete Relief of Regurgitation Symptoms
Time frame:
4 weeks
Reported as:
Median · days
The Median Time to Complete Relief of Regurgitation Symptoms
daysRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Median Time to Complete Relief of Regurgitation Symptoms9 (7 to 12)11 (8 to 14)13 (10 to 15)
PrimaryThe Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4

Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.

Time frame:
4 weeks
Reported as:
Number · participants
The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4
participantsRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4281283276
Statistical analysis
  • Rabeprazole 20 mg/Day vs Esomeprazole 40 mg/Day · non-inferiority · p = <0.05 (All statistical tests were interpreted at the 5% significance level (2-tailed).) · Proportion difference: -0.051Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%
PrimaryThe Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4

Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.

Time frame:
4 weeks
Reported as:
Number · participants
The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4
participantsRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4405418414
Statistical analysis
  • Rabeprazole 20 mg/Day vs Esomeprazole 40 mg/Day · non-inferiority · p = <0.05 (Adjustment for multiple comparisons was not made. The a priori threshold for statistical significance was p\<0.05. Tests were 2-sided except for the non-inferiority test which was 1-sided.) · Proportion difference: -0.053Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%
PrimaryThe Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4

Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.

Time frame:
4 weeks
Reported as:
Number · participants
The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4
participantsRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4397413402
Statistical analysis
  • Rabeprazole 20 mg/Day vs Esomeprazole 40 mg/Day · non-inferiority · p = <0.05 (Adjustment for multiple comparisons was not made. The a priori threshold for statistical significance was p\<0.05. Tests were 2-sided except for the non-inferiority test which was 1-sided.) · Proportion difference: -0.061Non inferiority was considered proven if the lower confidence interval of the one sided 95% CI of P(rab20)-P(e40) was above -9%
SecondaryThe Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods
Time frame:
4 weeks
Reported as:
Mean · percent of participants
The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods
percent of participantsRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods56.3 (53.1 to 59.5)63.4 (60.2 to 66.6)56.1 (52.9 to 59.3)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 20 mg/Day—5/464 (1.1%)151/464 (32.5%)
Esomeprazole 40 mg/Day—1/469 (0.2%)155/469 (33%)
Esomeprazole 20 mg/Day—9/459 (2%)158/459 (34.4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
lower respiratory tract infectionInfections and infestations0/4640/4691/459
alleged assaultSocial circumstances0/4640/4691/459
chest painGeneral disorders0/4640/4691/459
feverGeneral disorders0/4640/4691/459
perianal abscess drainageSurgical and medical procedures0/4640/4691/459
urinary retentionRenal and urinary disorders0/4640/4691/459
depressionPsychiatric disorders0/4640/4691/459
vomitingGastrointestinal disorders0/4640/4691/459
hypotensionVascular disorders0/4640/4691/459
meniscal tear of right kneeInjury, poisoning and procedural complications1/4640/4690/459
Most frequent other events
Showing 10 of 12
Most frequent other events
EventRabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/Day
Gastrointestinal signs and symptomsGastrointestinal disorders63/46467/46954/459
Gastrointestinal motility and defaecation condGastrointestinal disorders24/46429/46936/459
HeadachesNervous system disorders19/46424/46931/459
Infections - pathogen class unspecifiedInfections and infestations21/4649/46926/459
Viral infectious disordersInfections and infestations9/4646/46913/459
Neurological disorders NECNervous system disorders9/4649/46911/459
Salivary gland conditionsGastrointestinal disorders2/4648/4694/459
Joint disordersMusculoskeletal and connective tissue disorders2/4648/4693/459
Musculoskeletal and connective tissue disorders NECMusculoskeletal and connective tissue disorders7/4648/4696/459
Muscle disordersMusculoskeletal and connective tissue disorders4/4642/4694/459

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/DayTotal
Mean45.8 ± 14.848 ± 14.746.2 ± 14.846.7 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/DayTotal
Female204208208620
Male260261251772
Region of Enrollment
Region of Enrollment(participants)Rabeprazole 20 mg/DayEsomeprazole 40 mg/DayEsomeprazole 20 mg/DayTotal
Australia4644694591392
08

Study locations

25 sites
  • Belconnen, Australia
  • Bondi Junction, Australia
  • Brookvale, Australia
  • Browns Plains, Australia
  • Campbelltown, Australia
  • Campsie, Australia
  • Caringbah, Australia
  • Castle Hill, Australia
  • Charlestown, Australia
  • Dapto, Australia
  • Darlinghurst, Australia
  • Dubbo, Australia
  • Elizabeth, Australia
  • Fairfield, Australia
  • Hoppers Crossing, Australia
  • Ingleburn, Australia
  • Leichhardt, Australia
  • Maroubra, Australia
  • Melton, Australia
  • Mount Druitt, Australia
  • Oaklands Park, Australia
  • Royal Park, Australia
  • Sydney, Australia
  • Wentworthville, Australia
  • Wyoming, Australia
09

References and documents

Publications

  • Biscola FT, Abe CM, Guth BE. Determination of adhesin gene sequences in, and biofilm formation by, O157 and non-O157 Shiga toxin-producing Escherichia coli strains isolated from different sources. Appl Environ Microbiol. 2011 Apr;77(7):2201-8. doi: 10.1128/AEM.01920-10. Epub 2011 Feb 11. PubMed 21317257 ↗
  • Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G; Treat Study Group. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther. 2009 May 1;29(9):967-78. doi: 10.1111/j.1365-2036.2009.03948.x. Epub 2009 Feb 3. PubMed 19210493 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2007
First posted
Apr 23, 2007
Start
Nov 2006
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Aug 30, 2010
Last update
Apr 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00464308
Responsible party
Sponsor
First posted
Apr 23, 2007
Start date
Nov 2006
Primary completion
May 2008
Completion
May 2008
Results posted
Aug 30, 2010
Last update
Apr 21, 2014

Study contacts

Janssen-Cilag Pty Ltd Clinical Trial
study director · Janssen-Cilag Pty Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esomeprazole · Rabeprazole

Start the discussion